Host responses in tissue repair and fibrosis

Annual Review of Pathology: Mechanisms of Disease

Volumn 8, Issue , 2013, Pages 241-276

  Duffield, Jeremy S ^a   Lupher, Mark ^b   Thannickal, Victor J ^c   Wynn, Thomas A ^d  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Promedior Inc   (United States)

^c University of Alabama at Birmingham   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Fibrocyte; Fibrotic disease; Myofibroblast; Pericyte

Indexed keywords

ADAMTS1 PROTEIN; ALPHA SMOOTH MUSCLE ACTIN; AMBRISENTAN; BARDOXOLONE METHYL; BOSENTAN; CALVASCULIN; COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; FIBRONECTIN; GAMMA1B INTERFERON; GLIAL FIBRILLARY ACIDIC PROTEIN; HERMES ANTIGEN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; NINTEDANIB; PIRFENIDONE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; REACTIVE OXYGEN METABOLITE; SCLEROPROTEIN; SILDENAFIL; SPHINGOSINE 1 PHOSPHATE; SYNAPTOPHYSIN; SYNAPTOPODIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRANSFORMING GROWTH FACTOR; UNINDEXED DRUG; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BONE MARROW CELL; CALCIUM BINDING; CAPILLARY BASEMENT MEMBRANE; CELL COMMUNICATION; CELL DEDIFFERENTIATION; CELL DIFFERENTIATION; CELL POPULATION; COLLAGEN SYNTHESIS; COMPLEMENT SYSTEM; CYTOKINE PRODUCTION; EFFECTOR CELL; EMBRYO DEVELOPMENT; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; EXTRACELLULAR MATRIX; FIBROBLAST; FIBROGENESIS; FIBROSIS; FUNCTIONAL STATUS; HUMAN; IMMUNE RESPONSE; IMMUNODETECTION; INFLAMMATORY CELL; INNATE IMMUNITY; LEUKOCYTE; LUNG DEVELOPMENT; LUNG FIBROBLAST; LUNG FIBROSIS; MACROPHAGE; MACROPHAGE ACTIVATION; MESENCHYMAL STROMA CELL; MESENCHYME CELL; MUSCLE ISOMETRIC CONTRACTION; MYOFIBROBLAST; NONHUMAN; PERICYTE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SKELETAL MUSCLE; SMOOTH MUSCLE FIBER; STRESS FIBER; T LYMPHOCYTE; TH17 CELL; TISSUE INJURY; TISSUE REGENERATION; TISSUE REPAIR; URETER OBSTRUCTION; WNT SIGNALING PATHWAY; WOUND HEALING; ANIMAL; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; CELL COMMUNICATION; EXTRACELLULAR MATRIX; FIBROSIS; HUMANS; MYOFIBROBLASTS; PERICYTES; WOUND HEALING;

MLCS; MLOWN;

EID: 84872334083     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev-pathol-020712-163930     Document Type: Review

References (250)

1. Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, et al. 2009. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139:891-9066
2. Burmolle M, Thomsen TR, Fazli M, Dige I, Christensen L, et al. 2010. Biofilms in chronic infections - a matter of opportunity - monospecies biofilms in multispecies infections. FEMS Immunol. Med. Microbiol. 59:324-366
3. Wynn TA. 2008. Cellular and molecular mechanisms of fibrosis. J. Pathol. 214:199-2100
4. Wynn TA, Barron L. 2010. Macrophages: master regulators of inflammation and fibrosis. Semin. Liver Dis. 30:245-577
5. Hinz B, Phan SH, Thannickal VJ, Prunotto M, Desmouliere A, et al. 2012. Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. Am. J. Pathol. 180:1340-555
6. Gabbiani G, Majno G. 1972. Dupuytren's contracture: fibroblast contraction? An ultrastructural study. Am. J. Pathol. 66:131-466
7. Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G. 2007. The myofibroblast: one function, multiple origins. Am. J. Pathol. 170:1807-166
8. Kuhn C, McDonald JA. 1991. The roles of the myofibroblast in idiopathic pulmonary fibrosis. Ultrastructural and immunohistochemical features of sites of active extracellular matrix synthesis. Am. J. Pathol. 138:1257-655
9. Hinz B, GabbianiG,Chaponnier C. 2002. TheNH2-terminal peptide ofα-smoothmuscle actin inhibits force generation by the myofibroblast in vitro and in vivo. J. Cell Biol. 157:657-633
10. Castella LF, Buscemi L, Godbout C, Meister JJ, Hinz B. 2010. A new lock-step mechanism of matrix remodelling based on subcellular contractile events. J. Cell Sci. 123:1751-600
11. Hinz B, Mastrangelo D, Iselin CE, Chaponnier C, Gabbiani G. 2001. Mechanical tension controls granulation tissue contractile activity and myofibroblast differentiation. Am. J. Pathol. 159:1009-200
12. Wells RG. 2005. The role of matrix stiffness in hepatic stellate cell activation and liver fibrosis. J. Clin. Gastroenterol. 39:S158-611
13. Wipff PJ, Rifkin DB,Meister JJ, Hinz B. 2007. Myofibroblast contraction activates latent TGF-β1 from the extracellular matrix. J. Cell Biol. 179:1311-233
14. Huang X, Gai Y, Yang N, Lu B, Samuel CS, et al. 2011. Relaxin regulates myofibroblast contractility and protects against lung fibrosis. Am. J. Pathol. 179:2751-655
15. Peyrol S, Raccurt M, Gerard F, Gleyzal C, Grimaud JA, Sommer P. 1997. Lysyl oxidase gene expression in the stromal reaction to in situ and invasive ductal breast carcinoma. Am. J. Pathol. 150:497-5077
16. Olsen KC, Sapinoro RE, Kottmann RM, Kulkarni AA, Iismaa SE, et al. 2011. Transglutaminase 2 and its role in pulmonary fibrosis. Am. J. Respir. Crit. CareMed. 184:699-7077
17. Larios JM, Budhiraja R, Fanburg BL, Thannickal VJ. 2001. Oxidative protein cross-linking reactions involving L-tyrosine in transforming growth factor β1-stimulated fibroblasts. J. Biol. Chem. 276:17437- 411
18. Ross R, EverettNB, Tyler R. 1970. Wound healing and collagen formation. VI. The origin of the wound fibroblast studied in parabiosis. J. Cell Biol. 44:645-544
19. Scholten D, Osterreicher CH, Scholten A, Iwaisako K, Gu G, et al. 2010. Genetic labeling does not detect epithelial-to-mesenchymal transition of cholangiocytes in liver fibrosis in mice. Gastroenterology 139:987-988
20. Taura K, Miura K, Iwaisako K, Osterreicher CH, Kodama Y, et al. 2010. Hepatocytes do not undergo epithelial-mesenchymal transition in liver fibrosis in mice. Hepatology 51:1027-366
21. Lin S-L, Kisseleva T, Brenner DA, Duffield JS. 2008. Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am. J. Pathol. 173:1617- 277
22. Humphreys BD, Lin SL, Kobayashi A, Hudson TE, Nowlin BT, et al. 2010. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am. J. Pathol. 176:85- 977
23. Rock JR, Barkauskas CE, Cronce MJ, Xue Y, Harris JR, et al. 2011. Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition. Proc. Natl. Acad. Sci. USA 108:e1475-833
24. Duffield JS. 2011. Starting the scar: a primary role for pericytes? Nat. Med. 17:1052-533
25. Goritz C, Dias DO, Tomilin N, Barbacid M, Shupliakov O, Frisen J. 2011. A pericyte origin of spinal cord scar tissue. Science 333:238-422
26. Johnson RJ, Floege J, Yoshimura A, Iida H, Couser WG, Alpers CE. 1992. The activated mesangial cell: a glomerular "myofibroblast"? J. Am. Soc. Nephrol. 2:190-97SS
27. Rudolph R, McClure WJ, Woodward M. 1979. Contractile fibroblasts in chronic alcoholic cirrhosis. Gastroenterology 76:704-99
28. Rudolph R. 1979. Inhibition of myofibroblasts by skin grafts. Plast. Reconstr. Surg. 63:473-800
29. Bioulac-Sage P, Quinton A, Saric J, Grimaud JA, Mourey MS, Balabaud C. 1988. Chance discovery of hepatic fibrosis in patient with asymptomatic hypervitaminosis A. Arch. Pathol. Lab. Med. 112:505-99
30. Strutz F, Okada H, Lo CW, Danoff T, Carone RL, et al. 1995. Identification and characterization of a fibroblast marker: FSP1. J. Cell Biol. 130:393-4055
31. Markwald R, EisenbergC, Eisenberg L, TruskT, Sugi Y. 1996. Epithelial-mesenchymal transformations in early avian heart development. Acta Anat. 156:173-866
32. Bucala R, SpiegelLA, Chesney J,HoganM,CeramiA. 1994. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol. Med. 1:71-811
33. Naik-Mathuria B, Pilling D, Crawford JR, Gay AN, Smith CW, et al. 2008. Serum amyloid P inhibits dermal wound healing. Wound Repair Regen. 16:266-733
34. Pilling D, Buckley CD, Salmon M, Gomer RH. 2003. Inhibition of fibrocyte differentiation by serum amyloid P. J. Immunol. 171:5537-466
35. Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, et al. 2007. Endothelial-tomesenchymal transition contributes to cardiac fibrosis. Nat. Med. 13:952-611
36. Kida Y, Duffield JS. 2011. Pivotal role of pericytes in kidney fibrosis. Clin. Exp. Pharmacol. Physiol. 38:417-233
37. Le Hir M, Hegyi I, Cueni-Loffing D, Loffing J, Kaissling B. 2005. Characterization of renal interstitial fibroblast-specific protein 1/S100A4-positive cells in healthy and inflamed rodent kidneys. Histochem. Cell Biol. 123:335-466
38. Mlodzik K, Loffing J, Le Hir M, Kaissling B. 1995. Ecto-5-nucleotidase is expressed by pericytes and fibroblasts in the rat heart. Histochem. Cell Biol. 103:227-366
39. Osterreicher CH, Penz-Osterreicher M, Grivennikov SI, Guma M, Koltsova EK, et al. 2011. Fibroblastspecific protein 1 identifies an inflammatory subpopulation of macrophages in the liver. Proc. Natl. Acad. Sci. USA 108:308-133
40. Gustafsson E, Brakebusch C, Hietanen K, Fassler R. 2001. Tie-1-directed expression of Cre recombinase in endothelial cells of embryoid bodies and transgenic mice. J. Cell Sci. 114:671-766
41. De PalmaM, Venneri MA, Galli R, Sergi Sergi L, Politi LS, et al. 2005. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8:211-266
42. Kriz W, Kaissling B, Le Hir M. 2011. Epithelial-mesenchymal transition (EMT) in kidney fibrosis: fact or fantasy? J. Clin. Investig. 121:468-744
43. Zeisberg M, Duffield JS. 2010. Resolved: EMT produces fibroblasts in the kidney. J. Am. Soc. Nephrol. 21:1247-533
44. Peduto L, Reuter VE, Sehara-Fujisawa A, Shaffer DR, Scher HI, Blobel CP. 2006. ADAM12 is highly expressed in carcinoma-associated stroma and is required for mouse prostate tumor progression. Oncogene 25:5462-666
45. Dulauroy S, Vives FL, Eberl G, Peduto L. 2012. Lineage tracing of ADAM12+ perivascular cells reveals a dominant profibrotic pathway in injured tissues. Nat. Med. 18: In presss
46. Rojas A, Chang FC, Lin SL, Duffield JS. 2012. Contribution of perivascular cells in kidney interstitial injury. Clin. Nephrol. 77:400-88
47. Asada N, Takase M, Nakamura J, Oguchi A, Asada M, et al. 2011. Dysfunction of fibroblasts of extrarenal origin underlies renal fibrosis and renal anemia in mice. J. Clin. Investig. 121:3981-900
48. Chu AS, Diaz R, Hui JJ, Yanger K, Zong Y, et al. 2011. Lineage tracing demonstrates no evidence of cholangiocyte epithelial-to-mesenchymal transition in murine models of hepatic fibrosis. Hepatology 53:1685-955
49. Wells RG. 2010. The epithelial-to-mesenchymal transition in liver fibrosis: here today, gone tomorrow? Hepatology 51:737-400
50. Duffield JS. 2010. Epithelial to mesenchymal transition in injury of solid organs: fact or artifact? Gastroenterology 139:1081-833
51. Koesters R, Kaissling B, Lehir M, PicardN, Theilig F, et al. 2010. Tubular overexpression of transforming growth factor β1 induces autophagy and fibrosis but not mesenchymal transition of renal epithelial cells. Am. J. Pathol. 177:632-433
52. Bielesz B, Sirin Y, Si H, Niranjan T, Gruenwald A, et al. 2010. Epithelial Notch signaling regulates interstitial fibrosis development in the kidneys of mice and humans. J. Clin. Investig. 120:4040-544
53. Li L, Zepeda-Orozco D, Black R, Lin F. 2010. Autophagy is a component of epithelial cell fate in obstructive uropathy. Am. J. Pathol. 176:1767-788
54. Scholten D, Reichart D, Paik YH, Lindert J, Bhattacharya J, et al. 2011. Migration of fibrocytes in fibrogenic liver injury. Am. J. Pathol. 179:189-988
55. Duffield JS, Humphreys BD. 2010. Origin of new cells in the adult kidney: results from genetic labeling techniques. Kidney Int. 79:494-5011
56. Apte MV,Haber PS, Applegate TL, Norton ID, McCaughan GW, et al. 1998. Periacinar stellate shaped cells in rat pancreas: identification, isolation, and culture. Gut 43:128-333
57. Geerts A, Niki T, Hellemans K, De Craemer D, Van Den Berg K, et al. 1998. Purification of rat hepatic stellate cells by side scatter-activated cell sorting. Hepatology 27:590-988
58. Mellgren AM, Smith CL, Olsen GS, Eskiocak B, Zhou B, et al. 2008. Platelet-derived growth factor receptor β signaling is required for efficient epicardial cell migration and development of two distinct coronary vascular smooth muscle cell populations. Circ. Res. 103:1393-4011
59. Murphy MM, Lawson JA, Mathew SJ, Hutcheson DA, Kardon G. 2011. Satellite cells, connective tissue fibroblasts and their interactions are crucial for muscle regeneration. Development 138:3625-377
60. Mathew SJ, Hansen JM, Merrell AJ, Murphy MM, Lawson JA, et al. 2010. Connective tissue fibroblasts and Tcf4 regulate myogenesis. Development 138:371-844
61. Smith CL, Tallquist MD. 2010. PDGF function in diverse neural crest cell populations. Cell Adhes. Migr. 4:561-666
62. Rouget C. 1873. Memoire sur le developpement, la structure et les proprietés physiologiques des capillaires sanguins et lymphatiques. Arch. Physiol. Norm. Pathol. 5:603-633
63. Zimmerman K. 1923. Der feinere Bau der Blutcapillaren. Z. Anat. Entwickl. 68:29-366
64. Armulik A, Abramsson A, Betsholtz C. 2005. Endothelial/pericyte interactions. Circ. Res. 97:512-233
65. Schrimpf C, Duffield JS. 2011. Mechanisms of fibrosis: the role of the pericyte. Curr. Opin. Nephrol. Hypertens. 20:297-3055
66. Krueger M, Bechmann I. 2009. CNS pericytes: concepts, misconceptions, and a way out. Glia 58:1-100
67. Rhodin JA. 1968. Ultrastructure of mammalian venous capillaries, venules, and small collecting veins. J. Ultrastruct. Res. 25:452-5000
68. Courtoy PJ, Boyles J. 1983. Fibronectin in the microvasculature: localization in the pericyte-endothelial interstitium. J. Ultrastruct. Res. 83:258-733
69. Stratman AN,Malotte KM,Mahan RD, Davis MJ, Davis GE. 2009. Pericyte recruitment during vasculogenic tube assembly stimulates endothelial basement membrane matrix formation. Blood 114:5091-1011
70. Lin SL, Chang FC, Schrimpf C, Chen YT,Wu CF, et al. 2011. Targeting endothelium-pericyte cross talk by inhibiting VEGF receptor signaling attenuates kidney microvascular rarefaction and fibrosis. Am. J. Pathol. 178:911-233
71. Grgic I, Duffield JS, Humphreys BD. 2012. The origin of interstitial myofibroblasts in chronic kidney disease. Pediatr. Nephrol. 27:183-933
72. Hatini V, Huh SO, Herzlinger D, Soares VC, Lai E. 1996. Essential role of stromal mesenchyme in kidney morphogenesis revealed by targeted disruption of winged helix transcription factor BF-2. Genes Dev. 10:1467-788
73. Zhang H, Palmer R, Gao X, Kreidberg J, Gerald W, et al. 2003. Transcriptional activation of placental growth factor by the forkhead/winged helix transcription factor FoxD1. Curr. Biol. 13:1625-299
74. Sponheim J, Pollheimer J, Olsen T, Balogh J, Hammarstrom C, et al. 2010. Inflammatory bowel disease-associated interleukin-33 is preferentially expressed in ulceration-associated myofibroblasts. Am. J. Pathol. 177:2804-155
75. Friedman SL,Roll FJ, Boyles J, ArensonDM, BissellDM.1989. Maintenance of differentiated phenotype of cultured rat hepatic lipocytes by basement membrane matrix. J. Biol. Chem. 264:10756-622
76. Kisseleva T, Cong M, Paik Y-H, Scholten D, Jiang C, et al. 2012. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc. Natl. Acad. Sci. USA 109:9448-533
77. Schaffner F, Popper H. 1963. Capillarization of hepatic sinusoids in man. Gastroenterology 44:239-422
78. Das A, Shergill U, Thakur L, Sinha S, Urrutia R, et al. 2010. Ephrin B2/EphB4 pathway in hepatic stellate cells stimulates Erk-dependent VEGF production and sinusoidal endothelial cell recruitment. Am. J. Physiol. Gastrointest. Liver Physiol. 298:908-155
79. Semela D, Das A, Langer D, Kang N, Leof E, Shah V. 2008. Platelet-derived growth factor signaling through ephrin-b2 regulates hepatic vascular structure and function. Gastroenterology 135:671-799
80. Passman JN, Dong XR,Wu SP, Maguire CT,HoganKA, et al. 2008. A sonic hedgehog signaling domain in the arterial adventitia supports resident Sca1+ smooth muscle progenitor cells. Proc. Natl. Acad. Sci. USA 105:9349-544
81. Olson LE, Soriano P. 2011. PDGFRβsignaling regulates mural cell plasticity and inhibits fat development. Dev. Cell 20:815-266
82. Yang S, Yao B, Zhou Y, Yin H, ZhangMZ, Harris RC. 2012. Intrarenal dopamine modulates progressive angiotensin II-mediated renal injury. Am. J. Physiol. Renal Physiol. 302:742-499
83. Thadhani R, Pascual M, Bonventre JV. 1996. Acute renal failure. N. Engl. J. Med. 334:1448-600
84. Yang L, BesschetnovaTY, Brooks CR, Shah JV, Bonventre JV. 2010. Epithelial cell cycle arrest inG2/M mediates kidney fibrosis after injury. Nat. Med. 16:535-433
85. Schor SL. 1995. Fibroblast subpopulations as accelerators of tumor progression: the role of migration stimulating factor. EXS 74:273-966
86. Sato S, Kubota T, Suzuki Y. 1990. Composition and function of noncollagenous proteins in alveolar bone. Bull. Kanagawa Dent. Coll. 18:119-255
87. Jadrich JL, O'ConnorMB, Coucouvanis E. 2006. The TGFβactivated kinase TAK1 regulates vascular development in vivo. Development 133:1529-411
88. Oshima M, Oshima H, Taketo MM. 1996. TGF-βreceptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis. Dev. Biol. 179:297-3022
89. Dickson MC, Martin JS, Cousins FM, Kulkarni AB, Karlsson S, Akhurst RJ. 1995. Defective haematopoiesis and vasculogenesis in transforming growth factor β 1 knock out mice. Development 121:1845-544
90. Chen YT, Chang FC, Wu CF, Chou YH, Hsu HL, et al. 2011. Platelet-derived growth factor receptor signaling activates pericyte-myofibroblast transition in obstructive and post-ischemic kidney fibrosis. Kidney Int. 80:1170-811
91. Lindahl P, Johansson BR, Leveen P, Betsholtz C. 1997. Pericyte loss and microaneurysm formation in PDGF-β-deficient mice. Science 277:242-455
92. Bostrom H,Willetts K, PeknyM, Leveen P, Lindahl P, et al. 1996. PDGF-A signaling is a critical event in lung alveolar myofibroblast development and alveogenesis. Cell 85:863-733
93. Liu Y, Meyer C, Muller A, Herweck F, Li Q, et al. 2011. IL-13 induces connective tissue growth factor in rat hepatic stellate cells via TGF-β-independent Smad signaling. J. Immunol. 187:2814-233
94. Fabian SL, Penchev RR, Jacques BS, Rao AN, Sipila P, et al. 2012. Hedgehog-Gli pathway activation during kidney fibrosis. Am. J. Pathol. 180:1441-533
95. Ding L, Saunders TL, Enikolopov G, Morrison SJ. 2012. Endothelial and perivascular cells maintain haematopoietic stem cells. Nature 481:457-622
96. Dill MT, Rothweiler S, Djonov V, Hlushchuk R, Tornillo L, et al. 2012. Disruption of Notch1 induces vascular remodeling, intussusceptive angiogenesis, and angiosarcomas in livers of mice. Gastroenterology 142:967-777
97. Seki E, De Minicis S, Gwak GY, Kluwe J, Inokuchi S, et al. 2009. CCR1 and CCR5 promote hepatic fibrosis in mice. J. Clin. Investig. 119:1858-700
98. Vinas O, Bataller R, Sancho-Bru P, Gines P, Berenguer C, et al. 2003. Human hepatic stellate cells show features of antigen-presenting cells and stimulate lymphocyte proliferation. Hepatology 38:919-299
99. Hughes J, Liu Y, Van Damme J, Savill J. 1997. Human glomerular mesangial cell phagocytosis of apoptotic neutrophils: mediation by a novel CD36-independent vitronectin receptor/thrombospondin recognition mechanism that is uncoupled from chemokine secretion. J. Immunol. 158:4389-977
100. Sargent JL, Milano A, Bhattacharyya S, Varga J, Connolly MK, et al. 2010. A TGFβ-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity. J. Investig. Dermatol. 130:694-7055
101. Gabbiani G. 1981. The myofibroblast: a key cell for wound healing and fibrocontractive diseases. Prog. Clin. Biol. Res. 54:183-944
102. Desmouliere A, Redard M, Darby I, Gabbiani G. 1995. Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar. Am. J. Pathol. 146:56-666
103. Thannickal VJ, Horowitz JC. 2006. Evolving concepts of apoptosis in idiopathic pulmonary fibrosis. Proc. Am. Thorac. Soc. 3:350-566
104. Thannickal VJ, Lee DY, White ES, Cui Z, Larios JM, et al. 2003. Myofibroblast differentiation by transforming growth factor β1 is dependent on cell adhesion and integrin signaling via focal adhesion kinase. J. Biol. Chem. 278:12384-899
105. Horowitz JC, Lee DY, Waghray M, Keshamouni VG, Thomas PE, et al. 2004. Activation of the prosurvival phosphatidylinositol 3-kinase/AKT pathway by transforming growth factor β1 in mesenchymal cells is mediated by p38 MAPK-dependent induction of an autocrine growth factor. J. Biol. Chem. 279:1359-677
106. Horowitz JC, Rogers DS, Sharma V, Vittal R,White ES, et al. 2007. Combinatorial activation of FAK and AKT by transforming growth factor β1 confers an anoikis-resistant phenotype to myofibroblasts. Cell Signal. 19:761-711
107. VittalR,Horowitz JC, Moore BB, ZhangH,Martinez FJ, et al. 2005. Modulation of prosurvival signaling in fibroblasts by a protein kinase inhibitor protects against fibrotic tissue injury. Am. J. Pathol. 166:367-755
108. Phan SH, Zhang K, Zhang HY, Gharaee-Kermani M. 1999. The myofibroblast as an inflammatory cell in pulmonary fibrosis. Curr. Top. Pathol. 93:173-822
109. Otte JM, Rosenberg IM, Podolsky DK. 2003. Intestinal myofibroblasts in innate immune responses of the intestine. Gastroenterology 124:1866-788
110. Wallach-Dayan SB, Golan-Gerstl R, Breuer R. 2007. Evasion of myofibroblasts from immune surveillance: a mechanism for tissue fibrosis. Proc. Natl. Acad. Sci. USA 104:20460-655
111. Golan-Gerstl R, Wallach-Dayan SB, Amir G, Breuer R. 2007. Epithelial cell apoptosis by Fas ligand- positive myofibroblasts in lung fibrosis. Am. J. Respir. Cell Mol. Biol. 36:270-755
112. Wang R, RamosC, Joshi I, Zagariya A, Pardo A, et al. 1999. Human lungmyofibroblast-derived inducers of alveolar epithelial apoptosis identified as angiotensin peptides. Am. J. Physiol. Lung Cell. Mol. Physiol. 277:1158-644
113. Hagimoto N, Kuwano K, Inoshima I, YoshimiM, Nakamura N, et al. 2002. TGF-β1 as an enhancer of Fas-mediated apoptosis of lung epithelial cells. J. Immunol. 168:6470-788
114. Waghray M, Cui Z, Horowitz JC, Subramanian IM, Martinez FJ, et al. 2005. Hydrogen peroxide is a diffusible paracrine signal for the induction of epithelial cell death by activated myofibroblasts. FASEB J. 19:854-566
115. Levine A, Tenhaken R, Dixon R, Lamb C. 1994. H2O2 from the oxidative burst orchestrates the plant hypersensitive disease resistance response. Cell 79:583-933
116. Shirasu K, Dixon RA, Lamb C. 1996. Signal transduction in plant immunity. Curr. Opin. Immunol. 8:3-77
117. Niethammer P, Grabher C, Look AT,Mitchison TJ. 2009. A tissue-scale gradient of hydrogen peroxide mediates rapid wound detection in zebrafish. Nature 459:996-999
118. Babior BM, Curnutte JT,McMurrich BJ. 1976. The particulate superoxide-forming system from human neutrophils. Properties of the system and further evidence supporting its participation in the respiratory burst. J. Clin. Investig. 58:989-966
119. Ha EM,Oh CT, Bae YS, LeeWJ. 2005. A direct role for dual oxidase in Drosophila gut immunity. Science 310:847-500
120. Bedard K, Krause KH. 2007. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol. Rev. 87:245-3133
121. Cucoranu I, Clempus R, Dikalova A, Phelan PJ, Ariyan S, et al. 2005. NAD(P)H oxidase 4 mediates transforming growth factor β1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ. Res. 97:900-77
122. Amara N, Goven D, Prost F, Muloway R, Crestani B, Boczkowski J. 2010. NOX4/NADPH oxidase expression is increased in pulmonary fibroblasts from patients with idiopathic pulmonary fibrosis and mediates TGFβ1-induced fibroblast differentiation into myofibroblasts. Thorax 65:733-388
123. Hecker L, Vittal R, Jones T, Jagirdar R, Luckhardt TR, et al. 2009. NADPH oxidase 4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat. Med. 15:1077-811
124. Carnesecchi S, Deffert C, Donati Y, Basset O, Hinz B, et al. 2011. A key role for NOX4 in epithelial cell death during development of lung fibrosis. Antioxid. Redox Signal. 15:607-199
125. Pache JC, Carnesecchi S, Deffert C, Donati Y, Herrmann FR, et al. 2011. NOX-4 is expressed in thickened pulmonary arteries in idiopathic pulmonary fibrosis. Nat. Med. 17:31-322
126. Mittal M, Roth M, Konig P, Hofmann S, Dony E, et al. 2007. Hypoxia-dependent regulation of nonphagocytic NADPH oxidase subunit NOX4 in the pulmonary vasculature. Circ. Res. 101:258-677
127. Zhang Y, Lee TC, Guillemin B, Yu MC, RomWN. 1993. Enhanced IL-1βand tumor necrosis factor α release and messenger RNA expression in macrophages from idiopathic pulmonary fibrosis or after asbestos exposure. J. Immunol. 150:4188-966
128. Piguet PF, CollartMA, Grau GE, Sappino AP, Vassalli P. 1990. Requirement of tumour necrosis factor for development of silica-induced pulmonary fibrosis. Nature 344:245-477
129. Piguet PF, Collart MA, Grau GE, Kapanci Y, Vassalli P. 1989. Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. J. Exp. Med. 170:655-633
130. Nawroth I, Alsner J, Behlke MA, Besenbacher F, Overgaard J, et al. 2010. Intraperitoneal administration of chitosan/DsiRNA nanoparticles targetingTNFαprevents radiation-induced fibrosis. Radiother. Oncol. 97:143-488
131. Bahcecioglu IH, Koca SS, Poyrazoglu OK, Yalniz M, Ozercan IH, et al. 2008. Hepatoprotective effect of infliximab, an anti-TNF-α agent, on carbon tetrachloride-induced hepatic fibrosis. Inflammation 31:215-211
132. Gabele E, Froh M, Arteel GE, Uesugi T, Hellerbrand C, et al. 2009. TNFαis required for cholestasisinduced liver fibrosis in the mouse. Biochem. Biophys. Res. Commun. 378:348-533
133. Tomita K, Tamiya G, Ando S, Ohsumi K, Chiyo T, et al. 2006. Tumour necrosis factor α signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut 55:415-244
134. He X, Mekasha S, Mavrogiorgos N, Fitzgerald KA, Lien E, Ingalls RR. 2010. Inflammation and fibrosis during Chlamydia pneumoniae infection is regulated by IL-1 and the NLRP3/ASC inflammasome. J. Immunol. 184:5743-544
135. Gasse P, Mary C, Guenon I, Noulin N, Charron S, et al. 2007. IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice. J. Clin. Investig. 117:3786- 999
136. Vilaysane A, Chun J, SeamoneME, Wang W, Chin R, et al. 2010. TheNLRP3 inflammasome promotes renal inflammation and contributes to CKD. J. Am. Soc. Nephrol. 21:1732-444
137. Piguet PF, VesinC,GrauGE, Thompson RC. 1993. Interleukin 1 receptor antagonist (IL-1RA) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica. Cytokine 5:57-611
138. BujakM, FrangogiannisNG. 2009. The role of IL-1 in the pathogenesis of heart disease. Arch. Immunol. Ther. Exp. 57:165-766
139. Jones LK, O'Sullivan KM, Semple T, Kuligowski MP, Fukami K, et al. 2009. IL-1RI deficiency ameliorates early experimental renal interstitial fibrosis. Nephrol. Dial. Transplant. 24:3024-322
140. Kamari Y, Shaish A, Vax E, Shemesh S, Kandel-Kfir M, et al. 2011. Lack of interleukin-1α or interleukin-1β inhibits transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic mice. J. Hepatol. 55:1086-944
141. Wilson MS, Madala SK, Ramalingam TR, Gochuico BR, Rosas IO, et al. 2010. Bleomycin and IL-1 β-mediated pulmonary fibrosis is IL-17A dependent. J. Exp. Med. 207:535-522
142. Vesey DA, Cheung CW, Cuttle L, Endre ZA, Gobe G, Johnson DW. 2002. Interleukin-1β induces human proximal tubule cell injury,α- smoothmuscle actin expression and fibronectin production. Kidney Int. 62:31-400
143. Fan JM, Huang XR, Ng YY, Nikolic-Paterson DJ, Mu W, et al. 2001. Interleukin-1 induces tubular epithelial-myofibroblast transdifferentiation through a transforming growth factor β1-dependent mechanism in vitro. Am. J. Kidney Dis. 37:820-311
144. Lonnemann G, Engler-Blum G,Muller GA, Koch KM, Dinarello CA. 1995. Cytokines in human renal interstitial fibrosis. II. Intrinsic interleukin (IL)-1 synthesis and IL-1-dependent production of IL-6 and IL-8 by cultured kidney fibroblasts. Kidney Int. 47:845-544
145. Lonnemann G, Shapiro L, Engler-Blum G, Muller GA, Koch KM, Dinarello CA. 1995. Cytokines in human renal interstitial fibrosis. I. Interleukin-1 is a paracrine growth factor for cultured fibrosis-derived kidney fibroblasts. Kidney Int. 47:837-444
146. NatsumeM, Tsuji H, Harada A, AkiyamaM, Yano T, et al. 1999. Attenuated liver fibrosis and depressed serum albumin levels in carbon tetrachloride- treated IL-6-deficient mice. J. Leukoc. Biol. 66:601-88
147. Barnes TC, AndersonME, Moots RJ. 2011. The many faces of interleukin-6: the role of IL-6 in inflammation, vasculopathy, and fibrosis in systemic sclerosis. Int. J. Rheumatol. 2011:7216088
148. Diaz JA, Booth AJ, Lu G, Wood SC, Pinsky DJ, Bishop DK. 2009. Critical role for IL-6 in hypertrophy and fibrosis in chronic cardiac allograft rejection. Am. J. Transpl. 9:1773-833
149. RaghuG, Brown KK, Costabel U, Cottin V, du Bois RM, et al. 2008. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 178:948- 555
150. Simonian PL, Roark CL, Wehrmann F, Lanham AK, Diaz del Valle F, et al. 2009. Th17-polarized immune response in a murine model of hypersensitivity pneumonitis and lung fibrosis. J. Immunol. 182:657-655
151. Joshi AD, Fong DJ, Oak SR, Trujillo G, Flaherty KR, et al. 2009. Interleukin-17-mediated immunopathogenesis in experimental hypersensitivity pneumonitis. Am. J. Respir. Crit. CareMed. 179:705- 166
152. Dudas PL, Sague SL, Elloso MM, Farrell FX. 2011. Proinflammatory/ profibrotic effects of interleukin- 17A on human proximal tubule epithelium. Nephron. Exp. Nephrol. 117:e114-233
153. Faust SM, Lu G, Marini BL, Zou W, Gordon D, et al. 2009. Role of T cell TGFβsignaling and IL-17 in allograft acceptance and fibrosis associated with chronic rejection. J. Immunol. 183:7297-3066
154. Fan L, BensonHL, Vittal R,Mickler EA, Presson R, et al. 2011. Neutralizing IL-17 prevents obliterative bronchiolitis in murine orthotopic lung transplantation. Am. J. Transplant. 11:911-222
155. Feng W, Li W, Liu W, Wang F, Li Y, Yan W. 2009. IL-17 induces myocardial fibrosis and enhances RANKL/OPG and MMP/TIMP signaling in isoproterenol-induced heart failure. Exp. Mol. Pathol. 87:212-188
156. Wang LY, Chen SJ, Xu KS. 2011. IL-17 expression is correlated with hepatitis B-related liver diseases and fibrosis. Int. J. Mol. Med. 27:385-922
157. Miyamoto M, Prause O, Sj östrandM, Laan M, Lotvall J, Linden A. 2003. Endogenous IL-17 as a mediator of neutrophil recruitment caused by endotoxin exposure inmouse airways. J. Immunol. 170:4665-722
158. Laan M, Cui ZH, Hoshino H, Lotvall J, Sj östrand M, et al. 1999. Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. J. Immunol. 162:2347-522
159. Zhu F, Wang Q, Guo C, Wang X, Cao X, et al. 2011. IL-17 induces apoptosis of vascular endothelial cells - a potential mechanism for human acute coronary syndrome. Clin. Immunol. 141:152-600
160. Kinder BW, Brown KK, Schwarz MI, Ix JH, Kervitsky A, King TE Jr. 2008. Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis. Chest 133:226-322
161. Gasse P, Riteau N, Vacher R, Michel ML, Fautrel A, et al. 2011. IL-1 and IL-23 mediate early IL-17A production in pulmonary inflammation leading to late fibrosis. PLoS ONE 6:e231855
162. MiS, Li Z, Yang HZ,Liu H,WangJP, et al. 2011. Blocking IL-17A promotes the resolution of pulmonary inflammation and fibrosis viaTGF-β1-dependent and -independent mechanisms. J. Immunol. 187:3003- 144
163. Cortez DM, Feldman MD,Mummidi S, Valente AJ, Steffensen B, et al. 2007. IL-17 stimulates MMP-1 expression in primary human cardiac fibroblasts via p38 MAPK- and ERK1/2-dependent C/EBP-β, NF-κB, and AP-1 activation. Am. J. Physiol. Heart Circ. Physiol. 293:3356-655
164. Wynn TA, Cheever AW, JankovicD, Poindexter RW, Caspar P, et al. 1995. An IL-12-based vaccination method for preventing fibrosis induced by schistosome infection. Nature 376:594-966
165. Shi Z, Wakil AE, Rockey DC. 1997. Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses. Proc. Natl. Acad. Sci. USA 94:10663-688
166. Mavalia C, Scaletti C, Romagnani P, Carossino AM, Pignone A, et al. 1997. Type 2 helper T cell predominance and high CD30 expression in systemic sclerosis. Am. J. Pathol. 151:1751-588
167. Furuie H, Yamasaki H, Suga M, Ando M. 1997. Altered accessory cell function of alveolar macrophages: a possiblemechanism for induction of Th2 secretory profile in idiopathic pulmonary fibrosis. Eur. Respir. J. 10:787-944
168. Wallace WA, Ramage EA, Lamb D, Howie SE. 1995. A type 2 (Th2-like) pattern of immune response predominates in the pulmonary interstitium of patients with cryptogenic fibrosing alveolitis (CFA). Clin. Exp. Immunol. 101:436-411
169. Westermann W, Schobl R, Rieber EP, Frank KH. 1999. Th2 cells as effectors in postirradiation pulmonary damage preceding fibrosis in the rat. Int. J. Radiat. Biol. 75:629-388
170. Wynn TA. 2004. Fibrotic disease and the TH1/TH2 paradigm. Nat. Rev. Immunol. 4:583-944
171. Reiman RM, Thompson RW, Feng CG, Hari D, Knight R, et al. 2006. Interleukin-5 (IL-5) augments the progression of liver fibrosis by regulating IL-13 activity. Infect. Immun. 74:1471-799
172. Ong C, Wong C, Roberts CR, Teh HS, Jirik FR. 1998. Anti-IL-4 treatment prevents dermal collagen deposition in the tight-skin mouse model of scleroderma. Eur. J. Immunol. 28:2619-299
173. Chiaramonte MG, Donaldson DD, Cheever AW, Wynn TA. 1999. An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. J. Clin. Investig. 104:777-855
174. Zhu Z, Homer RJ, Wang Z, Chen Q, Geba GP, et al. 1999. Pulmonary expression of interleukin-13 causes inflammation,mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J. Clin. Investig. 103:779-888
175. Yang G, Volk A, Petley T, Emmell E, Giles-Komar J, et al. 2004. Anti-IL-13 monoclonal antibody inhibits airway hyperresponsiveness, inflammation and airway remodeling. Cytokine 28:224-322
176. MurrayLA, Argentieri RL,Farrell FX,BrachtM, Sheng H, et al. 2008. Hyper-responsiveness of IPF/UIP fibroblasts: interplay between TGFβ1, IL-13 and CCL2. Int. J. Biochem. Cell Biol. 40:2174-822
177. Kolodsick JE,Toews GB, Jakubzick C, HogaboamC,MooreTA, et al. 2004. Protection from fluorescein isothiocyanate-induced fibrosis in IL-13-deficient, but not IL-4-deficient, mice results from impaired collagen synthesis by fibroblasts. J. Immunol. 172:4068-766
178. Fuschiotti P. 2011. Role of IL-13 in systemic sclerosis. Cytokine 56:544-499
179. Oh MH,Oh SY, Yu J, Myers AC, LeonardWJ, et al. 2011. IL-13 induces skin fibrosis in atopic dermatitis by thymic stromal lymphopoietin. J. Immunol. 186:7232-422
180. Rankin AL, Mumm JB, Murphy E, Turner S, Yu N, et al. 2010. IL-33 induces IL-13-dependent cutaneous fibrosis. J. Immunol. 184:1526-355
181. HanG,Zhang H, XieCH, Zhou YF. 2011. Th2-like immune response in radiation-induced lung fibrosis. Oncol. Rep. 26:383-888
182. Heller F, Fuss IJ, Nieuwenhuis EE, Blumberg RS, Strober W. 2002. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NKT cells. Immunity 17:629-388
183. Weng HL, Liu Y, Chen JL,Huang T, Xu LJ, et al. 2009. The etiology of liver damage imparts cytokines transforming growth factor β1 or interleukin-13 as driving forces in fibrogenesis. Hepatology 50:230-433
184. Shimamura T, Fujisawa T, Husain SR, Kioi M, Nakajima A, Puri RK. 2008. Novel role of IL-13 in fibrosis induced by nonalcoholic steatohepatitis and its amelioration by IL-13R-directed cytotoxin in a rat model. J. Immunol. 181:4656-655
185. Lee CG, Homer RJ, Zhu Z, Lanone S, Wang X, et al. 2001. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor β1. J. Exp. Med. 194:809-211
186. Richter A, Puddicombe SM, Lordan JL, Bucchieri F, Wilson SJ, et al. 2001. The contribution of interleukin (IL)-4 and IL-13 to the epithelial-mesenchymal trophic unit in asthma. Am. J. Respir. Cell Mol. Biol. 25:385-911
187. Kaviratne M, Hesse M, Leusink M, Cheever AW, Davies SJ, et al. 2004. IL-13 activates a mechanism of tissue fibrosis that is completely TGF-βindependent. J. Immunol. 173:4020-299
188. Kuperman DA, Huang X, Koth LL, ChangGH, Dolganov GM, et al. 2002. Direct effects of interleukin- 13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma. Nat. Med. 8:885- 899
189. Lee JH, Kaminski N, Dolganov G, Grunig G, Koth L, et al. 2001. Interleukin-13 induces dramatically different transcriptional programs in three human airway cell types. Am. J. Respir. CellMol. Biol. 25:474- 855
190. Sempowski GD, Beckmann MP, Derdak S, Phipps RP. 1994. Subsets of murine lung fibroblasts express membrane-bound and soluble IL-4 receptors. Role of IL-4 in enhancing fibroblast proliferation and collagen synthesis. J. Immunol. 152:3606-144
191. Doucet C, Brouty-Boye D, Pottin-Clemenceau C, Canonica GW, Jasmin C, Azzarone B. 1998. Interleukin (IL)-4 and IL-13 act on human lung fibroblasts. Implication in asthma. J. Clin. Investig. 101:2129- 399
192. Oriente A, Fedarko NS, Pacocha SE, Huang SK, Lichtenstein LM, Essayan DM. 2000. Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. J. Pharmacol. Exp. Ther. 292:988-944
193. Jakubzick C, Choi ES, Kunkel SL, Joshi BH, Puri RK, Hogaboam CM. 2003. Impact of interleukin-13 responsiveness on the synthetic and proliferative properties ofTh1- and Th2-type pulmonary granuloma fibroblasts. Am. J. Pathol. 162:1475-866
194. Ramalingam TR, Pesce JT, Sheikh F, Cheever AW, Mentink-Kane MM, et al. 2008. Unique functions of the type II interleukin 4 receptor identified in mice lacking the interleukin 13 receptor α1 chain. Nat. Immunol. 9:25-333
195. Chiaramonte MG, Mentink-Kane M, Jacobson BA, Cheever AW, Whitters MJ, et al. 2003. Regulation and function of the interleukin 13 receptorα2 during aThelper cell type 2-dominant immune response. J. Exp. Med. 197:687-7011
196. Mentink-Kane MM, Cheever AW, Wilson MS, Madala SK, Beers LM, et al. 2011. Accelerated and progressive and lethal liver fibrosis in mice that lack interleukin (IL)-10, IL-12p40, and IL-13Rα2. Gastroenterology 141:2200-99
197. Gordon S. 2003. Alternative activation of macrophages. Nat. Rev. Immunol. 3:23-355
198. Mantovani A, Sica A, Locati M. 2005. Macrophage polarization comes of age. Immunity 23:344-466
199. LupherMLJr,GallatinWM.2006. Regulation of fibrosis by the immune system. Adv. Immunol. 89:245- 888
200. Duffield JS, Lupher ML Jr. 2010. PRM-151 (recombinant human serum amyloid P/pentraxin 2) for the treatment of fibrosis. Drug News Perspect. 23:305-155
201. Anders HJ, Ryu M. 2011. Renalmicroenvironments and macrophage phenotypes determine progression or resolution of renal inflammation and fibrosis. Kidney Int. 80:915-255
202. Herzog EL, Bucala R. 2010. Fibrocytes in health and disease. Exp. Hematol. 38:548-566
203. MosserDM, Edwards JP. 2008. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8:958-699
204. Duffield JS, Forbes SJ, Constandinou CM, Clay S, Partolina M, et al. 2005. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J. Clin. Investig. 115:56-655
205. Duffield JS, Tipping PG, Kipari T, Cailhier JF, Clay S, et al. 2005. Conditional ablation of macrophages halts progression of crescentic glomerulonephritis. Am. J. Pathol. 167:1207-199
206. Fallowfield JA, Mizuno M, Kendall TJ, Constandinou CM, Benyon RC, et al. 2007. Scar-associated macrophages are a major source of hepatic matrix metalloproteinase 13 and facilitate the resolution of murine hepatic fibrosis. J. Immunol. 178:5288-955
207. Lin SL, Castano AP, Nowlin BT, Lupher ML Jr, Duffield JS. 2009. Bone marrow Ly6Chigh monocytes are selectively recruited to injured kidney and differentiate into functionally distinct populations. J. Immunol. 183:6733-433
208. Bonner JC, Osornio-Vargas AR, Badgett A, Brody AR. 1991. Differential proliferation of rat lung fibroblasts induced by the platelet-derived growth factor AA, AB, and BB isoforms secreted by rat alveolar macrophages. Am. J. Respir. Cell Mol. Biol. 5:539-477
209. Henderson NC, Mackinnon AC, Farnworth SL, Kipari T, Haslett C, et al. 2008. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am. J. Pathol. 172:288-988
210. Karlmark KR,Weiskirchen R, Zimmermann HW, Gassler N, Ginhoux F, et al. 2009. Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis. Hepatology 50:261-744
211. Martinet Y,RomWN, Grotendorst GR,MartinGR, CrystalRG. 1987. Exaggerated spontaneous release of platelet-derived growth factor by alveolar macrophages from patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 317:202-99
212. Prasse A, Pechkovsky DV,Toews GB, JungraithmayrW,Kollert F, et al. 2006. A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. Am. J. Respir. Crit. CareMed. 173:781-922
213. Wahl SM, McCartney-Francis N, Allen JB, Dougherty EB, Dougherty SF. 1990. Macrophage production of TGF-βand regulation by TGF-β. Ann. N.Y. Acad. Sci. 593:188-966
214. Xing Z, Tremblay GM, Sime PJ, Gauldie J. 1997. Overexpression of granulocyte-macrophage colony- stimulating factor induces pulmonary granulation tissue formation and fibrosis by induction of transforming growth factor β1 and myofibroblast accumulation. Am. J. Pathol. 150:59-666
215. Yasuoka H, Yamaguchi Y, Feghali-Bostwick CA. 2009. The pro-fibrotic factor IGFBP-5 induces lung fibroblast and mononuclear cell migration. Am. J. Respir. Cell Mol. Biol. 41:179-888
216. Prasse A,Müller-QuernheimJ. 2009.Non-invasive biomarkers in pulmonary fibrosis. Respirology 14:788-955
217. Murray LA, Chen Q, Kramer MS, Hesson DP, Argentieri RL, et al. 2011. TGF-βdriven lung fibrosis is macrophage dependent and blocked by serum amyloid P. Int. J. Biochem. Cell Biol. 43:154-622
218. Baran CP, Opalek JM, McMaken S, Newland CA, O'Brien JM Jr, et al. 2007. Important roles for macrophage colony-stimulating factor, CC chemokine ligand 2, and mononuclear phagocytes in the pathogenesis of pulmonary fibrosis. Am. J. Respir. Crit. CareMed. 176:78-899
219. Crawford JR, Pilling D, Gomer RH. 2010. Improved serum-free culture conditions for spleen-derived murine fibrocytes. J. Immunol. Methods 363:9-200
220. Kulkarni O, Pawar RD, Purschke W, Eulberg D, Selve N, et al. 2007. Spiegelmer inhibition of CCL2/MCP-1 ameliorates lupus nephritis in MRL-(Fas)lpr mice. J. Am. Soc. Nephrol. 18:2350-588
221. Moreira AP, Cavassani KA, Hullinger R, Rosada RS, Fong DJ, et al. 2010. Serum amyloid P attenuates M2 macrophage activation and protects against fungal spore-induced allergic airway disease. J. Allergy Clin. Immunol. 126:712-211
222. Shao DD, Suresh R, Vakil V, Gomer RH, Pilling D. 2008. Pivotal advance: Th-1 cytokines inhibit, and Th-2 cytokines promote fibrocyte differentiation. J. Leukoc. Biol. 83:1323-333
223. Pilling D, Gomer R. 2007. Regulatory pathways for fibrocyte differentiation. In Fibrocytes: New Insights into Tissue Repair and Systemic Fibroses, ed. R Bucala, pp. 37-60. Singapore: World Sci.
224. Homer RJ, Herzog EL. 2010. Recent advances in pulmonary fibrosis: implications for scleroderma. Curr. Opin. Rheumatol. 22:683-899
225. Mehrad B, Burdick MD, Zisman DA, KeaneMP, Belperio JA, Strieter RM. 2007. Circulating peripheral blood fibrocytes in human fibrotic interstitial lung disease. Biochem. Biophys. Res. Commun. 353:104-88
226. Murray LA, Rosada R, Moreira AP, Joshi A, Kramer MS, et al. 2010. Serum amyloid P therapeutically attenuates murine bleomycin-induced pulmonary fibrosis via its effects on macrophages. PLoS ONE 5:e96833
227. Moeller A, Gilpin SE, Ask K, Cox G, Cook D, et al. 2009. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 179:588-944
228. Nishida M, Okumura Y, Fujimoto S, Shiraishi I, Itoi T, Hamaoka K. 2005. Adoptive transfer of macrophages ameliorates renal fibrosis in mice. Biochem. Biophys. Res. Commun. 332:11-166
229. Cabrera S, Gaxiola M, Arreola JL, Ramirez R, Jara P, et al. 2007. Overexpression of MMP9 in macrophages attenuates pulmonary fibrosis induced by bleomycin. Int. J. Biochem. Cell Biol. 39:2324-388
230. Shi J, Aisaki K, Ikawa Y,Wake K. 1998. Evidence of hepatocyte apoptosis in rat liver after the administration of carbon tetrachloride. Am. J. Pathol. 153:515-255
231. Popov Y, Sverdlov DY, Bhaskar KR, Sharma AK, Millonig G, et al. 2010. Macrophage-mediated phagocytosis of apoptotic cholangiocytes contributes to reversal of experimental biliary fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol. 298:323-344
232. Koronyo-Hamaoui M, Ko MK, Koronyo Y, Azoulay D, Seksenyan A, et al. 2009. Attenuation of ADlike neuropathology by harnessing peripheral immune cells: local elevation of IL-10 and MMP-9. J. Neurochem. 111:1409-244
233. Murai M, Turovskaya O, Kim G, Madan R, Karp CL, et al. 2009. Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis. Nat. Immunol. 10:1178-844
234. van Strien ME, Mercier D, Drukarch B, Breve JJ, Poole S, et al. 2010. Anti-inflammatory effect by lentiviral-mediated overexpression of IL-10 or IL-1 receptor antagonist in rat glial cells andmacrophages. Gene Ther. 17:662-711
235. Ji Z, Ke ZJ, Geng JG. 2011. SAP suppresses the development of experimental autoimmune encephalomyelitis in C57BL/6 mice. Immunol. Cell Biol. 90:388-955
236. ZhangM, Zhang J, YanM, Luo D, ZhuW, et al. 2010. A phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration. Ophthalmology 118:672-788
237. Bharadwaj D, Mold C, Markham E, Du Clos TW. 2001. Serum amyloid P component binds to Fcγ receptors and opsonizes particles for phagocytosis. J. Immunol. 166:6735-411
238. Mold C, GreshamHD,DuClosTW.2001. Serum amyloid P component and C-reactive protein mediate phagocytosis through murine FcγRs. J. Immunol. 166:1200-55
239. Bijl M, Horst G, Bijzet J, Bootsma H, Limburg PC, Kallenberg CG. 2003. Serum amyloid P component binds to late apoptotic cells and mediates their uptake by monocyte-derived macrophages. Arthritis Rheum. 48:248-544
240. Ciurana CL, Hack CE. 2006. Competitive binding of pentraxins and IgM to newly exposed epitopes on late apoptotic cells. Cell Immunol. 239:14-211
241. Familian A, Zwart B, Huisman HG, Rensink I, Roem D, et al. 2001. Chromatin-independent binding of serum amyloid P component to apoptotic cells. J. Immunol. 167:647-544
242. Mold C, Baca R, Du Clos TW. 2002. Serum amyloid P component and C-reactive protein opsonize apoptotic cells for phagocytosis through Fcγreceptors. J. Autoimmun. 19:147-544
243. Pilling D, Roife D, Wang M, Ronkainen SD, Crawford JR, et al. 2007. Reduction of bleomycininduced pulmonary fibrosis by serum amyloid P. J. Immunol. 179:4035-444
244. Haudek SB, Xia Y, Huebener P, Lee JM, Carlson S, et al. 2006. Bone marrow-derived fibroblast precursors mediate ischemic cardiomyopathy in mice. Proc. Natl. Acad. Sci. USA 103:18284-899
245. Haudek SB, Trial J, Xia Y, Gupta D, Pilling D, Entman ML. 2008. Fc receptor engagement mediates differentiation of cardiac fibroblast precursor cells. Proc. Natl. Acad. Sci. USA 105:10179-844
246. Zhang W, Wu J, Qiao B, Xu W, Xiong S. 2011. Amelioration of lupus nephritis by serum amyloid P component gene therapy with distinct mechanisms varied from different stage of the disease. PLoS ONE 6:e226599
247. Lu J, Marnell LL, Marjon KD, Mold C, Du Clos TW, Sun PD. 2008. Structural recognition and functional activation of FcγR by innate pentraxins. Nature 456:989-922
248. Manicassamy S, Reizis B, Ravindran R, Nakaya H, Salazar-Gonzalez RM, et al. 2010. Activation of β-catenin in dendritic cells regulates immunity versus tolerance in the intestine. Science 329:849-533
249. Li B, Castano AP, Hudson TE, Nowlin BT, Lin SL, et al. 2010. The melanoma-associated transmembrane glycoprotein Gpnmb controls trafficking of cellular debris for degradation and is essential for tissue repair. FASEB J. 24:4767-811
250. Martinez J, Almendinger J, Oberst A, Ness R, Dillon CP, et al. 2011. Microtubule-associated protein 1 light chain 3 α(LC3)-associated phagocytosis is required for the efficient clearance of dead cells. Proc. Natl. Acad. Sci. USA 108:17396-4011